Drug Discovery World

OCTOBER 12, 2023

You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. The post New online event: Innovative advances in neuroscience appeared first on Drug Discovery World (DDW).

Disease 130

Disease Science Drug Development Drugs 130

Drug Discovery World

JUNE 28, 2024

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. The trial will include an estimated 87 subjects with study sites located in the US, UK and Europe.

Therapies 147

Therapies Disease Medical Schools Trials 147

Drug Discovery World

FEBRUARY 21, 2023

We sought to clarify the impact of previous vaccination on cardiovascular events among people who develop COVID-19 and found that, particularly among those with comorbidities, such as previous MACE, type 2 diabetes, high cholesterol, liver disease, and obesity, there is an association with a lower risk of complications.

Vaccine 130

Vaccine Disease Research Drugs 130

Drug Discovery World

MARCH 15, 2024

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. All doses were well-tolerated and there were no serious adverse events.

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

JUNE 21, 2023

Join DDW for this exclusive free event, Comparing immune-humanized platforms: Which one is best for my application? The event will take place on July 6 at 3PM BST. The post Exclusive event: How to compare immune-humanized platforms appeared first on Drug Discovery World (DDW). which is supported by The Jackson Laboratory.

Immune Response 130

Immune Response Laboratories Regulations Research 130

Drug Discovery World

MAY 15, 2024

Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Specific numerical values (steps) denote the severity of NPDR, with 47-53 describing the moderately severe disease.

Disease 162

Disease Treatment Therapies Pharmaceuticals 162

Drug Discovery World

JUNE 23, 2023

PTC Therapeutics has shared interim data from the 12-week portion of the PIVOT-HD Phase II study of PTC518 in Huntington’s disease (HD) patients. PTC518 treatment was also demonstrated to be well tolerated, with no treatment-related serious adverse events, no reports of peripheral neuropathy or dose-limiting toxicities.

Disease 130

Disease Trials Treatment Drugs 130

Drug Discovery World

APRIL 19, 2024

Askbio’s AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson’s disease, was well tolerated with no serious adverse events in a Phase Ib clinical trial. The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado, USA.

Therapies 130

Therapies Disease Clinical Trials Trials 130

Drug Discovery World

JULY 15, 2022

Single cell and spatial tools from 10x Genomics are designed to deliver powerful, multiomic insights from complex disease samples that enable you to confidently fuel your target identification pipeline with the most promising candidates. The event is hosted by DDW and supported by 10x Genomics. Register for free here.

Science 130

Science Disease 130

Drug Discovery World

APRIL 13, 2023

A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin medication was found to reduce the increased risk of cardiovascular disease among people living with HIV. Adverse drug events observed in the study were like those in the general population taking statin therapy.

Disease 130

Disease Clinical Trials Trials Virus 130

Drug Discovery World

DECEMBER 1, 2022

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. Director, Application Development, LevitasBio will present the event. The event will take place on December 14, 2022 at 4PM GMT, 8AM PT.

RNA 130

RNA Clinical Trials Drugs Trials 130

Drug Discovery World

MARCH 6, 2023

The post Rhythm Pharmaceuticals buys biotech focused on rare disease appeared first on Drug Discovery World (DDW). Biopharmaceutical subsidiary Rhythm Pharmaceuticals Netherlands has acquired Xinvento, a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).

Disease 130

Disease Pharmaceuticals Therapies Treatment 130

Drugs.com

MAY 24, 2024

FRIDAY, May 24, 2024 -- Ozempic provides a wide variety of health benefits for people with kidney disease and type 2 diabetes, a major clinical trial has found. The drug significantly reduces the risk of severe kidney events, heart problems and.

Disease 124

Disease Clinical Trials Trials Drugs 124

Drug Discovery World

JANUARY 30, 2023

Cell and gene therapies (CGT) are transforming the way diseases are treated. The event will cover aspects affecting growth of the CGT market, including how manufacturing technologies are enabling drug development, what these therapies mean for the healthcare market, and the opportunities for developers.

Disease 130

Disease Treatment Therapies Drug Development 130

Drug Discovery World

JULY 19, 2023

Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.

Disease 130

Disease Trials Clinical Trials Therapies 130

Drug Discovery World

DECEMBER 11, 2023

The US Food and Drug Administration (FDA) has approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD), Casgevy and Lyfgenia. Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited.”

FDA Approval 130

FDA Approval Therapies FDA Disease 130

Science Daily: Pharmacology News

FEBRUARY 19, 2024

Researchers have identified a new pathway that contributes to cardiovascular disease associated with high levels of niacin, a common B vitamin previously recommended to lower cholesterol. The team discovered a link between 4PY, a breakdown product from excess niacin, and heart disease.

Disease 103

Disease Production Research 103

Chemical Biology and Drug Design

MAY 11, 2023

The figure depicts the neuroprotective role of crocin in Parkinson's disease. Abstract Parkinson's disease is among the most common forms of neurodegenerative illness, with present treatment being primarily symptomatic and frequently coming with substantial adverse effects.

Disease 100

Disease Research Clinical Trials Treatment 100

SCIENMAG: Medicine & Health

JANUARY 12, 2024

12, 2024) — The University of Kentucky will mark a decade of raising awareness and continuing its effort to warn women about the dangers of heart disease with the annual Healthy Hearts for Women Symposium. LEXINGTON, Ky. Credit: Peera_Sathawirawong, iStock/Getty Images Plus LEXINGTON, Ky.

Disease 82

Disease 82

Chemical Biology and Drug Design

FEBRUARY 13, 2024

Alzheimer's disease (AD) is a common age-related neurodegenerative brain disorder characterized by the impairment in memory and other cognitive functions. Abstract Alzheimer's disease (AD) is a common age-related neurodegenerative brain disorder characterized by the impairment in memory and other cognitive functions.

Disease 100

Disease Treatment Therapies Research 100

Drug Discovery World

FEBRUARY 27, 2024

The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease. High LDL-C is a major risk factor for coronary heart disease, heart attack, and stroke, and atherosclerosis is the leading cause of disease burden globally.

Vaccine 260

Vaccine Clinical Trials Disease Clinical Development 260

SCIENMAG: Medicine & Health

AUGUST 28, 2023

military veterans with coronary artery disease, suboptimal lipid-lowering therapy was prevalent in the clinical setting. Optimization of statin therapy was projected to produce clinically relevant reductions in the risks of death and cardiovascular events. About The Study: In this study of 111,000 U.S.

Therapies 84

Therapies Disease 84

BMG Labtech

OCTOBER 30, 2023

Cardiovascular disease, a group of disorders of the heart and blood vessels, is the number one cause of death across the world. One disorder in particular, atherosclerotic vascular disease, a chronic inflammatory disease associated with the formation of arterial plaques, is considered the major cause of cardiovascular diseases.

Disease 52

Disease Cell Based Assays Research Drugs 52

Drug Channels

APRIL 4, 2022

Rare Disease Innovation & Partnering Summit. Hybrid Event May 17-19, 2022 | Boston, MA www.informaconnect.com/rare. Don’t miss the Rare Disease Innovation & Partnering Summit, coming up May 17-19, 2022 in Boston, MA. Visit www.informaconnect.com/rare for further details and to register. d/b/a Drug Channels Institute.

Disease 98

Disease Therapies FDA Trials 98

Drug Discovery World

AUGUST 20, 2024

Join DDW and Lonza for this free event ‘ Building advanced cell models for toxicity testing ’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST.

Pharmacokinetics 130

Pharmacokinetics Production Science Pharmaceuticals 130

Conversations in Drug Development Trends

APRIL 5, 2024

For others, this rare day is aptly the day we honor rare disease communities. Observed annually on the last day of February since 2008, Rare Disease Day has grown into a global movement for raising awareness, promoting research, and advocating for improved access to rare disease treatments and support services.

Disease 52

Disease Clinical Trials Trials Treatment 52

Science Daily: Pharmacology News

JULY 5, 2023

Researchers have developed a soft, flexible, wireless device to monitor and treat heart disease and dysfunction in the days, weeks or months following traumatic heart-related events. And, after the device is no longer needed, it harmlessly dissolves inside the body, bypassing the need for extraction.

Disease 63

Disease Research 63

Drug Discovery World

APRIL 11, 2024

Biopharmaceutical company EpiEndo has completed a Phase IIA clinical trial for its therapy addressing chronic obstructive pulmonary disease (COPD). Damage of this barrier is implicated in several chronic inflammatory diseases, including COPD. ” 1: The Global Economic Burden of Noncommunicable Diseases.

Therapies 130

Therapies Clinical Trials Disease Trials 130

Fierce BioTech

SEPTEMBER 20, 2023

In this podcast interview, Dan Fisher, managing director and practice lead for IPM.ai, explains the use of artificial intelligence for stitching together key medical events that may happen over a r | IPM.ai helps brands assess a unique patient population, accelerate clinical trial recruitment, and optimize commercial outcomes

Disease 105

Disease Clinical Trials Trials 105

Drug Discovery World

AUGUST 2, 2024

MHRA approves semaglutide to reduce risk of cardiovascular events The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering from heart attacks or stroke. relative reduction in liver fat content (LFC), with up to 55.6%

Clinical Trials 130

Clinical Trials Drugs Disease Treatment 130

Broad Institute

JULY 6, 2023

The accuracy of these scores has improved for some diseases and groups of people, but they continue to fall short for those of non-European ancestry, mainly because the genetic datasets used to calculate these scores have largely come from people of European ancestry.

Disease 97

Disease DNA Hospitals Medical Schools 97

Drug Discovery World

AUGUST 29, 2023

Join DDW for this free event, ‘Discover how iPSC derived cells can be used to support the development of drug and gene therapies’, which is supported by DefiniGEN. The event will take place on 28 September 4PM BST, 5PM CEST, EDT 11AM, PDT 8AM. Register for free here. appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Disease Drugs 130

Elrig

MAY 18, 2023

The most important drug discovery event of the year? 18-19 October 2023 The most important drug discovery event of the year? It’s with great excitement that we announce the return of ELRIG’s FREE TO ATTEND Drug Discovery 2023 (DD 2023); Europe’s leading event for the drug discovery community! Save the date! Save the date!

Drugs 52

Drugs Science Research Therapies 52

Drug Discovery World

MAY 22, 2024

Join DDW for a free event on 18 June, 3PM BST to learn more about how patient-derived organoids are revolutionising drug discovery. What you will learn: How HUB Organoids overcome limitations of traditional models, providing a superior solution for disease modelling and drug development. Secure your place now.

Laboratories 147

Laboratories Disease Regulations Drug Development 147

The Pharma Data

JANUARY 4, 2021

Investors can pre-register for the event here. Eduardo Schiffrin, Medical Director, will participate in a panel discussion at the LifeSci Partners 10 th Annual Healthcare Corporate Access Event on Friday, January 8 from 11am Eastern Standard Time. Investors can pre-register for the event here. LAUSANNE, Switzerland, Jan.

Disease 40

Disease Therapies Treatment Production 40

Drug Discovery World

MAY 11, 2023

DDW’s Megan Thomas spoke with attendees, and comments on the event. Fundraising and investment Coming out of a global pandemic, in-person events initially added a degree of novelty to networking. At previous events, there has been an air of excitement but uncertainty of how quickly to adopt ‘business as usual’.

Targeted Protein Degradation 130

Targeted Protein Degradation Science Small Molecule Vaccine 130

Drug Discovery World

JUNE 12, 2024

Join DDW for a free event on 18 June, 3PM BST to learn more about how patient-derived organoids are revolutionising drug discovery. What you will learn: How HUB Organoids overcome limitations of traditional models, providing a superior solution for disease modelling and drug development. Secure your place now.

Laboratories 130

Laboratories Disease Regulations Drug Development 130